Results 21 to 30 of about 121,509 (248)

Chimeric Antigen Receptor Therapy

open access: yesNew England Journal of Medicine, 2018
Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors.
Carl H. June, Michel Sadelain
openaire   +3 more sources

Drug functional remapping: a new promise for tumor immunotherapy

open access: yesFrontiers in Oncology
The research and development of new anti-cancer drugs face challenges such as high costs, lengthy development cycles, and limited data on side effects.
Jiayi Dong   +27 more
doaj   +1 more source

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2021
Chimeric antigen receptor (CAR) T cells represent one of the newest frontiers of cell therapy. Their application currently involves relapsed/refractory aggressive B cell lymphoma and leukemia as a standard of care, while several studies are exploring CAR-
Eugenio Galli   +10 more
doaj   +1 more source

Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

open access: yesExperimental Biology and Medicine
Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells.
Yu Xiang   +18 more
doaj   +1 more source

In-depth analysis of the safety of CAR-T cell therapy for solid tumors

open access: yesFrontiers in Immunology
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy.
Jiayi Dong   +33 more
doaj   +1 more source

Natural killer cell immunotherapy in glioblastoma

open access: yesDiscover Oncology, 2022
Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments.
Hamed Hosseinalizadeh   +5 more
doaj   +1 more source

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

open access: yesBMC Cancer, 2018
Background Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis.
Yuji Makita   +7 more
doaj   +1 more source

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis

open access: yesCells, 2023
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment option for patients suffering from B-cell- and plasma cell-derived hematologic malignancies and is being adapted for the treatment of solid cancers. However, CAR T is associated with
Bryanna Reinhardt   +2 more
doaj   +1 more source

A TCR-based Chimeric Antigen Receptor

open access: yesScientific Reports, 2017
Effector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TCR) redirection.
Even Walseng   +8 more
doaj   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy